Sector News

Categories

Borderless Insights

Image
Negotiating Terms with a New Employer
Image
Beyond Flowers and Platitudes: Reclaiming the Essence of International Women’s Day
Image
Visionary or ‘Stuck-in-the-Mud’? Where are you on Workplace Flexibility?

AstraZeneca to carve out antibiotic R&D into separate firm

February 27, 2015
Life sciences
(Reuters) – Drugmaker AstraZeneca has decided to carve out its early-stage antibiotic research by creating a stand-alone subsidiary company, as it sharpens its focus on other therapy areas.
 
Chief Executive Pascal Soriot said last year he was looking to partner or sell its anti-infective business, which is no longer viewed as a core area for the British drugmaker.
 
AstraZeneca said in an emailed statement it would invest $40 million in the new antibiotic company, which will include early-stage products such as a drug in Phase II for gonorrhoea. The move will impact approximately 95 employees based in Waltham, Massachusetts.
 
The new structure has no impact on anti-infective products already on the market, including Merrem, Zinforo, Fluenz/Flumist and Synagis. It also does not affect Avycaz, a new antibiotic approved this week from Actavis, which was co-developed with AstraZeneca.
 
Antibiotics have fallen out of favour in the past decade among many Big Pharma companies, because of their typically low margins. The industry has focused instead on more profitable areas, like cancer.
 
More recently some companies have started coming back to the space, given the demand for novel medicines that can fight drug-resistant superbugs, with Merck & Co agreeing to buy Cubist for $8.4 billion in December.
 
But AstraZeneca prefers to deploy its resources on its three priority areas of oncology; cardiovascular and metabolic diseases; and respiratory and inflammation.
 
The decision to carve-out early-stage antibiotics fits with Soriot’s aim of doing more so-called “externalisation”, involving the sale of non-core drugs, both to increase the company’s focus and generate additional income to see it through a tough period of patient expiries on older drugs.
 
Last year it struck a partnership deal worth up to $500 million for Alzheimer’s treatment with Eli Lilly, which could be a model for further transactions.
 
(Reporting by Ben Hirschler, editing by William Hardy)

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

Read more
April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

Read more
April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

Read more
More news

How can we help you?

We're easy to reach